Marc Martens maintains a prominent position in our research with sources across Europe highlighting his fantastic work, which covers the full range of regulatory issues facing biotech, medical device and pharma clients.
Marc provides cutting edge strategic and regulatory advice to life sciences clients and represents them in litigation.
Marc is the co-head of the firm’s international life sciences and healthcare group, and head of the regulatory, public and administrative law group in Brussels.
Specialising in life sciences, he provides both contentious and non-contentious strategic advice to Belgian and international pharmaceutical, biotech and medical devices companies, as well as national and European industry associations facing complex regulatory frameworks. Marc's areas of expertise cover issues relating to life cycle management; clinical trials and data; data exclusivity; marketing; price and reimbursement authorisations; e-health; and distribution and advertising. He advises numerous biotech companies on a wide range of issues regarding advanced therapy medicinal products as well as the legal and bioethical issues relating to research and/or the use of human cells and tissues.
His public and administrative law expertise covers a full range of sub-practices such as public procurement and related litigation; environmental law; REACH; RoHS; WEES; and other Belgian and EU regulatory compliance issues. He advises companies, public bodies and industry associations on related matters.
Marc holds a law degree from the Vrije Universiteit Brussel (VUB) where he worked for four years as a research assistant; and a degree in public and administrative law from the University of Brussels (ULB). Before joining Bird & Bird, Marc was an expert adviser to the vice prime minister of Belgium for three years.
Marc regularly publishes and speaks on life sciences regulatory topics and provides an introduction to biotech law at the VUB. He is also a member of the board of the Belgian biotech sector organisation BIO.BE.